Last reviewed · How we verify
Covid-19 Sterilizing (COVID-19 Vaccine)
The COVID-19 Vaccine, developed by Pfizer, is a marketed drug for the prevention of COVID-19 in individuals 6 months of age and older. It has undergone 100 trials and has been the subject of 18,671 publications. The vaccine has generated $5.353 billion in revenue. The mechanism of action is not specified. The COVID-19 Vaccine has key indications for prevention of COVID-19 in various age groups. It has clinical differentiation from other COVID-19 vaccines. The commercial significance of the COVID-19 Vaccine is substantial, with high revenue and widespread use. Pipeline developments for the COVID-19 Vaccine are not specified.
At a glance
| Generic name | COVID-19 Vaccine |
|---|---|
| Also known as | Pfizer vaccine, Moderna vaccine, Johnson & Johnson vaccine, SARS-CoV-2 vaccine, Pfizer-BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine, COVID-19 Vaccine Moderna Intramuscular Injection |
| Sponsor | Pfizer |
| Drug class | vaccine |
| Target | SARS-CoV-2 |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Prevention of COVID-19 in individuals 6 months of age and older
- Prevention of COVID-19 in individuals 5 years of age and older for the Pfizer-BioNTech COVID-19 Vaccine
- Prevention of COVID-19 in individuals 6 months of age and older for the Moderna COVID-19 Vaccine
- Prevention of COVID-19 in individuals 6 months of age and older for the Novavax COVID-19 Vaccine
- Prevention of COVID-19 in individuals 12 years of age and older for the Janssen COVID-19 Vaccine
Common side effects
- Injection site pain (PAIN)
- Fatigue (FATIGUE)
- Headache (HEADACHE)
- Chills (CHILLS)
- Myalgia (MUSCLE PAIN)
- Arthralgia (JOINT PAIN)
- Diarrhoea (DIARRHEA)
- Injection site erythema (REDNESS)
- Pyrexia (FEVER)
- Injection site swelling (SWELLING)
- Vomiting (VOMITING)
- Upper respiratory tract infection
Drug interactions
- ACE inhibitors
- Angiotensin II receptor blockers
- Antiplatelets
- Anticoagulants
- Aspirin
- Blood thinners
- Corticosteroids
- Immunosuppressants
- Live vaccines
- Thalidomide
- Interferons
- Interleukin-2
Key clinical trials
- A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations (PHASE4)
- Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults (PHASE1)
- Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction (PHASE4)
- A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults (PHASE1)
- Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals (PHASE2, PHASE3)
- Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
- Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia. (PHASE3)
- COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Covid-19 Sterilizing CI brief — competitive landscape report
- Covid-19 Sterilizing updates RSS · CI watch RSS
- Pfizer portfolio CI